The stock closed at ₹0.54 on May 29, 2026, trading 41.94% below its 52-week high of ₹0.93 and has delivered a devastating one-year return of -40.00%, significantly underperforming the Sensex which declined 8.40% over the same period. The company's technical trend remains firmly bearish, with the stock trading below all major moving averages and institutional investors maintaining zero exposure to the counter.
Originally incorporated as Robinson Worldwide Trade Limited in 1994, the company underwent multiple name changes before settling on Johnson Pharmacare Limited in August 2021, when it pivoted its main business objects towards the pharmaceutical sector. However, this strategic repositioning has yet to translate into any meaningful operational activity or revenue generation.
Financial Performance: Complete Operational Standstill
The Q4 FY26 results paint a distressing picture of a company in severe financial distress. With zero revenue generation for the seventh consecutive quarter, Johnson Pharmacare reported an operating loss (PBDIT excluding other income) of ₹42.70 crores in Q4 FY26, marking the lowest operational performance in the company's recent history. This compares to a marginal operating loss of ₹0.01 crore in Q4 FY25, representing an exponential deterioration in operational metrics.
| Quarter | Net Sales (₹ Cr) | Operating Loss (₹ Cr) | Net Loss (₹ Cr) |
|---|---|---|---|
| Mar'26 | 0.00 | -42.70 | -55.61 |
| Dec'25 | 0.00 | -0.02 | -0.06 |
| Sep'25 | 0.00 | 0.00 | 0.00 |
| Jun'25 | 0.00 | -0.05 | -0.05 |
| Mar'25 | 0.00 | -0.01 | -0.51 |
| Dec'24 | 0.00 | -0.03 | -0.03 |
| Sep'24 | 0.00 | 0.00 | 0.00 |
The company recorded other income of ₹1.58 crores in Q4 FY26, a significant improvement from the negative other income of ₹0.33 crores in Q4 FY25. However, this was insufficient to offset the massive operational losses. Interest costs increased to ₹0.22 crores in Q4 FY26 from nil in the year-ago quarter, whilst employee costs remained minimal at ₹0.01 crore, suggesting an extremely lean organisational structure.
The profit before tax deteriorated sharply to ₹-55.61 crores in Q4 FY26 from ₹-0.51 crores in Q4 FY25, with the company paying zero taxes due to its loss-making status. The earnings per share for the quarter stood at ₹-1.01, the lowest on record, reflecting severe shareholder value destruction.
Critical Red Flag: Zero Revenue Generation
Johnson Pharmacare has reported zero net sales for seven consecutive quarters through March 2026, indicating a complete absence of operational business activity despite its stated pharmaceutical focus. The company's last recorded revenue was ₹2.00 crores in FY23, which declined from ₹3.00 crores in FY22, suggesting a progressive shutdown of business operations.
Balance Sheet Concerns: Eroding Capital Base
The company's balance sheet as of March 2025 reveals a shareholder equity base of ₹56.17 crores, comprising share capital of ₹55.00 crores and minimal reserves of ₹1.17 crores. The reserves have declined consistently from ₹1.95 crores in FY23 and ₹3.24 crores in FY22, reflecting ongoing losses eroding the capital base. At the current quarterly loss run rate, the company faces potential capital adequacy concerns within a few quarters.
Fixed assets stand at nil, whilst investments constitute ₹42.29 crores as of March 2025, down from ₹45.56 crores in the previous year. Current assets are minimal at ₹1.36 crores, whilst long-term debt stands at ₹0.61 crore. The company's return on equity (ROE) has plummeted to an alarming -4,146.00% in the latest quarter, whilst the return on capital employed (ROCE) stands at -196.60%, both metrics indicating catastrophic capital destruction and operational inefficiency.
Valuation Analysis: Extreme Overvaluation Despite Losses
Despite generating zero revenue and accumulating substantial losses, Johnson Pharmacare trades at an inexplicable price-to-book value ratio of 29.15x, representing a massive premium to its book value of ₹1.02 per share. The stock's current market price of ₹0.54 implies a market capitalisation of ₹30.00 crores for a company with no operational business, making it one of the most overvalued counters in the micro-cap space.
| Valuation Metric | Johnson Pharmacare | Assessment |
|---|---|---|
| P/E Ratio (TTM) | NA (Loss Making) | Not Applicable |
| Price to Book Value | 29.15x | Extremely Overvalued |
| EV/EBITDA | -1.18x | Negative (Loss Making) |
| Dividend Yield | NA | No Dividends |
The company's valuation grade is classified as "RISKY" by proprietary assessment metrics, having transitioned from "Very Expensive" in April 2023. With negative enterprise value multiples and no earnings to support any rational valuation framework, the current market price appears disconnected from fundamental reality.
Peer Comparison: Weakest Performer in Sector
Within the diversified commercial services sector, Johnson Pharmacare stands out for all the wrong reasons. A comparison with sector peers reveals the extent of underperformance and operational challenges facing the company.
| Company | P/E (TTM) | P/BV | ROE % | Debt/Equity |
|---|---|---|---|---|
| Johnson Pharmacare | NA (Loss Making) | 29.15x | 0.0% | 0.01 |
| SVC Industries | NA (Loss Making) | 0.15x | 0.0% | 0.66 |
| Evans Electric | NA (Loss Making) | 1.48x | 29.09% | -0.23 |
| S P Capital Finance | 9.51x | 1.25x | 5.54% | 4.55 |
| Shreevatsaa Finance | 62.14x | 1.37x | 0.0% | 0.00 |
Johnson Pharmacare trades at the highest price-to-book ratio (29.15x) amongst peers despite having nil ROE and zero operational revenue. This valuation anomaly is particularly stark when compared to Evans Electric, which trades at 1.48x book value whilst generating a healthy 29.09% ROE. The peer comparison underscores the fundamental disconnect between Johnson Pharmacare's market valuation and its operational reality.
Shareholding Pattern: Complete Retail Dominance
The shareholding structure of Johnson Pharmacare reveals a complete absence of institutional confidence. As of March 2026, non-institutional investors hold 100.00% of the company's equity, with zero promoter holding, zero foreign institutional investor (FII) participation, zero mutual fund exposure, and zero insurance company holdings.
| Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 |
|---|---|---|---|---|
| Promoter Holding | 0.00% | 0.00% | 0.00% | 0.00% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% |
| Mutual Fund Holding | 0.00% | 0.00% | 0.00% | 0.00% |
| Insurance Holdings | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-Institutional | 100.00% | 100.00% | 100.00% | 100.00% |
The absence of any promoter holding is particularly concerning, as it suggests a lack of management skin in the game and raises questions about accountability and strategic direction. The complete avoidance by sophisticated institutional investors—FIIs, mutual funds, and insurance companies—signals deep scepticism about the company's prospects and governance standards.
Stock Performance: Severe Wealth Destruction
Johnson Pharmacare's stock performance has been disastrous across most timeframes, with investors suffering severe capital erosion. The stock has declined 40.00% over the past year, massively underperforming the Sensex which fell 8.40% during the same period, resulting in a negative alpha of -31.60 percentage points.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | -1.82% | -0.85% | -0.97% |
| 1 Month | -8.47% | -3.51% | -4.96% |
| 3 Month | +3.85% | -8.01% | +11.86% |
| 6 Month | -11.48% | -12.75% | +1.27% |
| YTD | -6.90% | -12.26% | +5.36% |
| 1 Year | -40.00% | -8.40% | -31.60% |
| 2 Years | -50.00% | +0.37% | -50.37% |
| 3 Years | +3.85% | +18.98% | -15.13% |
The stock's risk-adjusted return stands at -1.10 with a volatility of 36.40%, placing it in the "HIGH RISK LOW RETURN" category—the worst possible quadrant for investors. The stock's beta of 1.50 indicates it is 50% more volatile than the broader market, amplifying downside risk during market corrections.
Technical indicators paint an equally bleak picture. The stock trades in a confirmed bearish trend, positioned below all major moving averages: 5-day MA (₹0.55), 20-day MA (₹0.56), 50-day MA (₹0.55), 100-day MA (₹0.55), and 200-day MA (₹0.62). The stock has declined 41.94% from its 52-week high of ₹0.93, though it remains 14.89% above its 52-week low of ₹0.47.
Quality Assessment: Does Not Qualify
Johnson Pharmacare's quality grade is classified as "DOES NOT QUALIFY" based on long-term financial performance metrics. The company exhibits zero sales growth over five years, zero EBIT growth, and an average ROCE of -21.82%—all indicative of sustained value destruction rather than creation.
Key quality deficiencies include an EBIT to interest coverage ratio of just 0.05x, suggesting the company cannot service its interest obligations from operating profits. The average sales to capital employed ratio stands at a paltry 0.04x, reflecting extremely poor asset productivity. With zero institutional holdings and no dividend payout history, the company fails to meet even basic quality thresholds expected of investable securities.
Investment Thesis: Multiple Red Flags Converge
The proprietary Mojo Score assigns Johnson Pharmacare an overall rating of 12 out of 100, firmly in the "STRONG SELL" category. This dismal score reflects the convergence of multiple critical risk factors:
⚠ Critical Risk Factors
- Zero Revenue Generation: No operational business activity for seven consecutive quarters through March 2026, indicating complete business standstill
- Massive Quarterly Loss: Q4 FY26 net loss of ₹55.61 crores represents catastrophic deterioration from ₹0.51 crore loss in Q4 FY25
- Severe Capital Erosion: ROE of -4,146.00% and ROCE of -196.60% indicate extreme shareholder value destruction
- Extreme Overvaluation: P/BV of 29.15x for a loss-making, zero-revenue company defies fundamental logic
- Zero Institutional Confidence: Complete absence of promoter, FII, MF, and insurance holdings signals deep scepticism
- Deteriorating Balance Sheet: Reserves declining from ₹3.24 crores (FY22) to ₹1.17 crores (FY25) as losses accumulate
- Bearish Technical Trend: Stock below all moving averages with confirmed bearish momentum
✓ Limited Positives
- Low Debt Burden: Minimal long-term debt of ₹0.61 crore reduces financial leverage risk
- No Promoter Pledging: Zero pledged shares eliminates this specific governance concern
- Investment Holdings: ₹42.29 crores in investments provides some asset backing, though declining
- Small Positive Alpha: YTD and 6-month periods show marginal outperformance vs Sensex, though from very low base
Outlook: Critical Monitoring Points
Given the severity of operational challenges and financial distress, investors must monitor specific catalysts and warning signals that could determine the company's survival or further deterioration.
Potential Positive Catalysts
- Commencement of revenue-generating pharmaceutical operations aligned with stated business objectives
- Strategic partnership or acquisition announcement to revive business activity
- Capital infusion or restructuring plan to stabilise financial position
- Management commentary explaining Q4 FY26 exceptional loss and forward strategy
Critical Red Flags to Monitor
- Continued zero revenue generation in Q1 FY27 and beyond
- Further deterioration in quarterly losses eroding remaining reserves
- Reserves falling below regulatory minimum thresholds triggering compliance issues
- Continued absence of institutional investor interest or promoter participation
- Lack of credible business plan or operational roadmap from management
- Stock breaching 52-week low of ₹0.47 on sustained selling pressure
The Verdict: Uninvestable at Current Juncture
Score: 12/100
For Fresh Investors: Completely avoid this counter. With zero revenue for seven quarters, a catastrophic ₹55.61 crore Q4 FY26 loss, and no institutional backing, Johnson Pharmacare represents extreme risk with no visible path to profitability. The stock's 29.15x P/BV ratio for a loss-making shell company defies rational valuation, making it a value trap rather than a value opportunity.
For Existing Holders: Exit positions at the earliest opportunity to limit further capital erosion. The company's operational standstill, deteriorating financials, and complete absence of institutional confidence suggest fundamental viability concerns. With reserves declining rapidly and no revenue visibility, the risk of further severe losses outweighs any speculative recovery potential.
Fair Value Estimate: ₹0.20-₹0.25 (63% downside from current price of ₹0.54), based on liquidation value of investments and minimal operational prospects
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions.
